Created at	Source	Raw Value	Validated value
Nov. 29, 2021, 10:30 p.m.	usa	GMT and GMI of neutralizing antibodies titers in phase 2;GMT and GMI of specific IgG total antibodies against Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) variants of SARS-CoV-2 in phase 2;Incidence and severity of adverse reactions in phase 1;Incidence and severity of solicited AEs in phase 2	GMT and GMI of neutralizing antibodies titers in phase 2;GMT and GMI of specific IgG total antibodies against Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) variants of SARS-CoV-2 in phase 2;Incidence and severity of adverse reactions in phase 1;Incidence and severity of solicited AEs in phase 2
Sept. 16, 2021, 5 a.m.	usa	GMT and GMI of neutralizing antibodies titers in phase 2;GMT and GMI of specific IgG total antibodies against Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) variants of SARS-CoV-2 in phase 2;Incidence and severity of adverse reactions in phase 1;Incidence and severity of solicited AEs in phase 2;The incidence of COVID-19 infections in phase 3	GMT and GMI of neutralizing antibodies titers in phase 2;GMT and GMI of specific IgG total antibodies against Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) variants of SARS-CoV-2 in phase 2;Incidence and severity of adverse reactions in phase 1;Incidence and severity of solicited AEs in phase 2;The incidence of COVID-19 infections in phase 3